MARKET

IBRX

IBRX

ImmunityBio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.38
+0.12
+0.70%
After Hours: 17.41 +0.03 +0.17% 19:46 04/16 EDT
OPEN
16.41
PREV CLOSE
17.26
HIGH
17.38
LOW
16.15
VOLUME
896.41K
TURNOVER
--
52 WEEK HIGH
45.42
52 WEEK LOW
3.040
MARKET CAP
6.66B
P/E (TTM)
-19.5941
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TV, PHUN, IBRX, FLXN, and FOLD.
PR Newswire - PRF · 2d ago
RIOT, MVIS, MSRT and FOLD among premarket gainers
Galectin Therapeutics (GALT) +27% as its belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer.Bit Digital (BTBT) +17%.UTStarcom Holdings (UTSI) +14%.Greenwich LifeSciences (GLSI) +15% after update on GP2 phase III clinical
Seekingalpha · 2d ago
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
Zacks.com · 04/09 20:18
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Zacks.com · 04/09 10:20
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
Benzinga · 04/08 14:59
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the ...
Business Wire · 04/08 14:00
ImmunityBio posts early-stage interim data showing potential of COVID-19 vaccine
Announcing preliminary Phase 1 data, ImmunityBio (IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against
Seekingalpha · 04/08 13:39
DJ ImmunityBio Sees Positive Results From Trial of Covid-19 Vaccine Candidate
Dow Jones · 04/08 13:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBRX. Analyze the recent business situations of ImmunityBio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBRX stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 12.39M
% Owned: 3.23%
Shares Outstanding: 383.18M
TypeInstitutionsShares
Increased
32
2.61M
New
31
1.05M
Decreased
23
279.15K
Sold Out
21
1.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+0.88%
Key Executives
Chairman/Executive Director
Patrick Soon-Shiong
President/Chief Executive Officer/Director
Richard Adcock
Chief Financial Officer/Chief Accounting Officer
David Sachs
Senior Vice President - Finance
Sonja Nelson
Other/Director
Barry Simon
Director
John Brennan
Director
Wesley Clark
Director
Cheryl Cohen
Director
Christobel Selecky
Independent Director
Michael Blaszyk
Independent Director
Linda Maxwell
No Data
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.

Webull offers kinds of Immunitybio Inc stock information, including NASDAQ:IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.